Welcome to our dedicated page for Claritev SEC filings (Ticker: CTEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Claritev Corporation (NYSE: CTEV) files a range of documents with the U.S. Securities and Exchange Commission that detail its operations as a healthcare technology, data and insights company. As an issuer of Class A common stock listed on the New York Stock Exchange, Claritev provides investors with periodic and current reports that describe its financial performance, capital structure, client relationships and key corporate events.
On this page, you can access Claritev’s SEC filings, including current reports on Form 8-K that the company uses to announce material developments. Recent 8-K filings have covered topics such as quarterly financial results, contract renewals with its ten largest clients, underwriting agreements for secondary offerings of Class A common stock by selling stockholders, and changes in executive roles. These filings also confirm that Claritev’s Class A common stock, with a par value of $0.0001 per share, is registered under Section 12(b) and trades under the symbol CTEV on the NYSE.
Claritev’s earnings-related filings and exhibits provide detail on revenues, net income or loss, and non-GAAP metrics such as EBITDA, Adjusted EBITDA, Free Cash Flow, Unlevered Free Cash Flow and an Adjusted cash conversion ratio. The company defines these measures and explains their limitations, giving investors insight into how management evaluates performance and cash generation alongside GAAP results.
Through Stock Titan, these filings are complemented by AI-powered summaries that help explain the significance of each document. Investors can quickly see the key points from Claritev’s 8-Ks, and, where available, review annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy materials and other disclosures. This page also provides a pathway to monitor any insider-related filings, such as Form 4 reports, that may be associated with Claritev’s equity compensation and ownership changes, offering a structured view of the company’s regulatory reporting history.
Albinson Brock reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp senior vice president and chief accounting officer Albinson Brock received a grant of 2,956 restricted stock units tied to Class A common stock. These units were awarded at no cash cost as part of his compensation.
The RSUs will vest in four equal installments of 25% each on March 31 of 2027, 2028, 2029, and 2030, aligning incentives over several years. After this award, Brock directly holds 30,193 shares of Claritev common stock.
Claritev Corporation is calling a virtual annual meeting on April 29, 2026 for holders of Class A stock as of March 6, 2026. Stockholders are being asked to elect four Class III directors, ratify PricewaterhouseCoopers LLP as auditor, approve executive pay on an advisory basis, and approve an amendment increasing shares under the 2020 Omnibus Incentive Plan.
Claritev positions itself as a healthcare technology, data and insights company focused on transparency and affordability. Management highlights a 2025 “Year of the Turn,” returning to revenue growth, stronger adjusted EBITDA and free cash flow, and more than $67 million in new annual contract value. The company processed $179.8 billion in medical charges, identifying $25.0 billion in potential cost savings, and reports 2025 total stockholder return of 189%.
The executive pay program centers on market-competitive salaries, annual cash incentives and equity awards. 2025 bonuses paid at 110% of target after the leadership team requested negative discretion to shift more of the pool to other employees. From 2026, 25% of long-term incentives for executives will be performance stock units tied to unlevered free cash flow. The proxy also details a classified 11-seat board with a lead independent director, extensive healthcare and technology experience, and committee oversight of risk, including cybersecurity and artificial intelligence, alongside a sustainability working group and plans for a 2025 Corporate Responsibility Report in the third quarter of 2026.
Claritev Corporation used its 2026 Investor Day to outline its strategy, financial guidance, and long-term goals for its healthcare cost-management and analytics platform. Management highlighted core businesses in claims intelligence, network solutions, and payment and revenue integrity, plus growth in data and analytics, international markets, and services.
For FY 2026, Claritev projects revenue of $980 million to $1 billion and Adjusted EBITDA of $605 million to $615 million, with total capital spend of $160 million to $170 million, an effective tax rate of 24% to 28%, and free cash flow of $0 to $10 million.
The company’s Vision 2030 model contemplates revenue of $1.3 billion and Adjusted EBITDA of $800 million, targeting an Adjusted EBITDA margin of roughly 61% to 64% and a path to reduce net leverage toward about 5.0x while increasing levered free cash flow.
Claritev Corp executive vice president and CFO Garis Douglas Michael bought shares of his company in the open market. On March 16, 2026, he purchased 1,300 shares of Class A common stock at $17.69 per share, bringing his direct holdings to 206,152 shares.
He also reports indirect ownership of additional Class A shares through retirement accounts, including 19,927 shares in his spouse's IRA and 45,810 shares in his own IRA, along with smaller positions in IRAs for his daughter and son. The filing shows a net-buy transaction with no reported sales.
Claritev Corp executive vice president and Chief Digital Officer Kim Michael bought 15,000 shares of Class A common stock in an open-market transaction at $16.50 per share on 2026-03-12, increasing direct ownership to 182,878 shares.
Claritev Corp SVP and General Counsel Tara O'Neil reported equity compensation activity and related tax withholdings. She received a grant of 18,130 shares of Class A common stock as restricted stock units at no cost, increasing her direct holdings to 43,113 shares.
To cover taxes on previously granted restricted stock units vesting on March 1 in 2022, 2023, 2024, and 2025, a total of 2,216 Class A shares were disposed of through tax-withholding transactions at $13.47 per share. In addition, 6,967 cash-settled restricted stock units granted in 2025 were settled in cash as 50% vested on March 1, 2026.
Claritev Corp director White Dale A. reported tax-related share dispositions tied to vesting restricted stock units. On March 1, 2026, a total of 14,158 shares of Class A common stock were withheld at $13.47 per share to cover tax obligations on RSU awards granted in 2022 and 2023.
After these tax-withholding dispositions, White directly holds 145,922 shares of Claritev Class A common stock. An additional 201,652 shares are listed as indirectly held by a trust. The transactions were not recorded as open-market purchases or sales but as payment of tax liabilities by delivering shares.
Claritev Corp EVP & CFO Garis Douglas Michael reported several equity-related transactions in Claritev Class A common stock and related units on March 1, 2026. He disposed of 25,488 cash-settled restricted stock units back to the issuer following vesting of cRSUs granted on March 1, 2025. He also had 5,331 Class A shares withheld to cover taxes tied to vesting of prior restricted stock units, and received a grant of 66,322 restricted stock units that vest in four equal annual installments on March 1 of 2027, 2028, 2029, and 2030. After these transactions, he reported 204,852 Class A shares held directly, plus additional indirect holdings in Individual Retirement Accounts for himself, his spouse, and children.
Claritev Corp EVP and Chief Digital Officer Kim Michael reported several equity-related transactions on March 1, 2026. The filing shows a grant of 34,487 shares of Class A common stock as restricted stock units that will vest 25% each year on March 1, 2027, 2028, 2029, and 2030. The company also withheld multiple small blocks of Class A common stock to cover taxes due on previously granted restricted stock units that vested on March 1 of 2022, 2023, 2024, and 2025. In addition, cash-settled restricted stock units granted on March 1, 2025 partially vested and were settled in cash, reducing the number of those units held.